Strategic Partners A/S

Strategic Partners A/S Liabilities

The The Liabilities of Strategic Partners A/S (STRAP.CO) as of Oct 16, 2026 is 1.15 M DKK. In the previous year, The Liabilities was 4.31 M DKK — a change of -73.34% (lower).

Liabilities

1.15 MDKK

YoY

-73.34%

Last updated:

In 2025, Strategic Partners A/S's total liabilities amounted to 1.15 M DKK, a -73.34% difference from the 4.31 M DKK total liabilities in the previous year.

The Strategic Partners A/S Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
53.10 M DKK
Jan 1, 2019
127.79 M DKK
Jan 1, 2020
201.97 M DKK
Jan 1, 2021
163.89 M DKK
Jan 1, 2022
15.85 M DKK
Jan 1, 2023
5.07 M DKK
Jan 1, 2024
4.31 M DKK
Jan 1, 2025
1.15 M DKK
The Strategic Partners A/S Liabilities history
YEARLiabilitiesYoY
1.15 MDKK-73.34%
4.31 MDKK-14.99%
5.07 MDKK-68.02%
15.85 MDKK-90.33%
163.89 MDKK-18.85%
201.97 MDKK+58.05%
127.79 MDKK+140.65%
53.10 MDKK+12.70%
47.12 MDKK+226.46%
14.43 MDKK+33.52%
10.81 MDKK+81.15%
5.97 MDKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Strategic Partners A/S Stock analysis

What does Strategic Partners A/S do? Strategic Partners A/S, listed on the Copenhagen Stock Exchange with ticker STRAP.CO and ISIN DK0062502894, is a Danish biotechnology company operating in the healthcare sector. Based in Copenhagen, the company employs 141 people and went public through an IPO on November 17, 2017. Strategic Partners A/S focuses on the development of treatments for rare diseases, particularly targeting lysosomal storage diseases (LSDs) and protein aggregation disorders. LSDs encompass approximately 50 genetic disorders caused by deficiencies in lysosomal enzymes or other lysosomal components. The company's primary therapeutic candidate, arimoclomol, works by stimulating the production of heat shock proteins, which assist in correcting misfolded proteins or facilitating their removal via lysosomal recycling. Strategic Partners A/S collaborates with academic institutions across Europe and the United States to advance its research and development efforts. The company's website is hosted at https://www.orphazyme.com/, though the provided source description includes unverified details about Orphazyme A/S, which should not be conflated with Strategic Partners A/S. Strategic Partners A/S is dedicated to addressing life-threatening and debilitating rare diseases through innovative biotechnological approaches. The company's operations are centered on preclinical development, with a focus on advancing therapies that target the underlying mechanisms of genetic disorders. Strategic Partners A/S maintains a strong presence in the biotechnology sector, leveraging partnerships and scientific expertise to develop treatments for conditions with limited therapeutic options. The company's activities are aligned with the broader healthcare industry's focus on rare disease research and treatment innovation. Strategic Partners A/S continues to work toward bringing novel therapies to patients suffering from rare and complex genetic disorders. Strategic Partners A/S is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Strategic Partners A/S's Liabilities

Strategic Partners A/S's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Strategic Partners A/S's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Strategic Partners A/S's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Strategic Partners A/S's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Strategic Partners A/S’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Strategic Partners A/S stock

The Liabilities of Strategic Partners A/S is 1.15 M DKK in 2025.

The Liabilities of Strategic Partners A/S changed from 4.31 M DKK to 1.15 M DKK, representing a -73.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Strategic Partners A/S since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Strategic Partners A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Strategic Partners A/S

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Strategic Partners A/S